AUSTIN, Texas - Vermillion, Inc. (NASDAQ: VRML) a bioanalytical-based womens health company focused on gynecologic disease, today announced the appointment of Nancy G. Cocozza to its Board of Directors. Ms. Cocozza joins the Board effective August 17, 2018, and brings the Board composition to six members.
We warmly welcome Nancy to our Board, said Valerie Palmieri, President and CEO of Vermillion. Nancy will be a tremendous asset to us, as she brings over three decades of managed care leadership and reimbursement experience. Her insights and perspective will prove invaluable as Vermillion launches new offerings to expand its womens health product line. In addition, women now represent half of our board; truly a milestone for our womens health company!
Ms. Cocozza stated, I am excited to join Vermillions Board of Directors as the Company leads the efforts in creating a new standard of care in ovarian cancer and womens health. I look forward to contributing to the Companys success in a big way.
Ms. Nancy Cocozza recently retired in June 2018 from the position of President of the Medicare Business for Aetna, where she was responsible for Aetnas Medicare strategy, growth and operating results; she led a team that, at the time of her retirement, served more than 4 million Medicare members nationwide through a robust portfolio of Medicare Advantage plans, Medicare prescription drug plans and Medicare Supplement plans. Prior to Aetna, Ms. Cocozza was Executive Vice President at HealthMarkets, an individual market health insurance provider, where she led the Medicare division. She also led the government insurance programs at Coventry Health Care. Ms. Cocozza began her career at Aetna, where she spent 16 years building and leading various commercial managed care operations. Ms. Cocozza holds a B.S. degree in accounting from Philadelphia University.